ShareValue scores for 0JXI.LSE: Valuation 33, Quality 27, Growth 50, Health 48.
0JXI.LSELSE
Madrigal Pharmaceuticals Inc.
£5.15
(+1.24%)
0JXI.LSELSE
Madrigal Pharmaceuticals Inc.
£5.15(+1.24%)
Loading chart...
Sentiment
Verdicts
Value:Overvalued
Quality:Weak
Growth:Moderate
Health:Moderate
Verdicts
Fundamental Rating
Value Trap Risk
Expected Return
-7% to 11%
Rating
Trap Risk
Return
-7% to 11%
Valuation
33
Overvalued
Price vs Value
Quality
27
Weak
Business Strength
Growth
50
Moderate
Revenue & Earnings
Health
48
Moderate
Financial Stability
Momentum
53
Neutral
Price Trend
Company Details
About
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Sector
IndustryN/A
ExchangeLSE
Market Cap$79M
P/E RatioN/A
Dividend YieldNone
Sector Rank#2093
Score Analysis
AI Investment Thesis
Data as of:Aug 7, 2026
|Last calculated:Aug 7, 2026